Functional Belly Dancer Dyskinesia Associated with Abdominal Pain: A Case Series
Objective: To describe belly dancer dyskinesia (BDD) presenting as a manifestation of functional movement disorder associated with abdominal pain, and to emphasize the role of…Movement Disorder Phenotypes in Neuronal Antibody–Mediated Autoimmune Encephalitis
Objective: To characterize movement disorder phenotypes in neuronal antibody–mediated autoimmune encephalitis (AE) and assess associations with specific antibody subtypes. Background: Neuronal antibody–mediated AE is a…Low-dose ketamine reduces dopamine 2 receptor-like agonist-induced dyskinesia in a preclinical model
Objective: Preclinical evaluation of low-dose ketamine treatment on dyskinesia induced by direct or indirect striatofugal pathway activation. Background: Ketamine infusions are effective therapy for depression…When Presynaptic Stimulation is Not Enough: Severe Biphasic Dyskinesia on LECIG Reversed by Postsynaptic Apomorphine Rescue
Objective: To report an exceptional case of advanced Parkinson’s disease (PD) where levodopa/carbidopa/entacapone intestinal gel (LECIG) failed to provide adequate motor control, ultimately requiring a…Physical Proximity Influences Mobility in Advanced Parkinson’s Disease Patient–Caregiver Dyads.
Objective: To investigate the relationship between physical proximity within advanced Parkinson’s disease (PD) patient–caregiver dyads and the mobility of each dyad member during daily life.…Foslevodopa-Foscarbidopa Continuous Subcutaneous Infusion Leads to Long-Term Reduction in Dyskinesia in Parkinson’s Disease: Results from 5-Year Follow-Up
Objective: To investigate the long-term impact of foslevodopa-foscarbidopa continuous subcutaneous infusion (CSCI) on dyskinesia in Parkinson’s disease (PD). Background: Foslevodopa-foscarbidopa CSCI is an emerging treatment…Beta–motor state correspondence as a predictor of adaptive deep brain stimulation benefit in Parkinson’s disease
Objective: To clarify practical factors for optimizing adaptive deep brain stimulation (aDBS) to achieve better clinical outcomes in Parkinson’s disease (PD). Background: aDBS is a…A Large-Scale Digital Parkinson Disease Platform Matches Clinician Identification of Dyskinesia and Uncovers Unmet Need Between Visits
Objective: To evaluate whether continuous remote monitoring can identify dyskinesia at scale, detect between-visit worsening, and support more efficient patient-clinician communication about management. Background: Dyskinesia…Levodopa-Induced Dyskinesias in Patients with Parkinson’s Disease in the Uzbek Population
Objective: To investigate the clinical features and prevalence of levodopa-induced dyskinesias in patients with Parkinson’s disease in the Uzbek population. Background: Levodopa-induced dyskinesias (LID) are…Oral D1-like/D2-like Receptor Agonist, Lu AF28996, Provides Robust Antiparkinsonian Efficacy with Reduced Dyskinesia in the MPTP-Macaque Model
Objective: Evaluate the therapeutic potential of Lu AF28996 in the MPTP-macaque model of PD. Background: Chronic levodopa treatment is associated with the development of motor…
- 1
- 2
- 3
- …
- 49
- Next Page »